Hartsol PlusInjection

Hartsol Plus Injection is a iv infusion manufactured by Libra Infusions Ltd. in Bangladesh. Its active ingredient is Dextrose & Hartmann's Solution.

Indications

This solution is indicated as a source of water, electrolytes and calories or as an alkalinizing agent.

Contraindications

Solutions containing dextrose may be contraindicated in patients with known allergy to corn or corn products.

Composition

• Each 100 ml contains
• 5 gm Dextrose
• 600 mg Sodium Chloride
• 310 mg Sodium Lactate
• 30 mg Potassium Chloride
• 20 mg Calcium Chloride

Pharmacology

This is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment and caloric supply in a single dose container for intravenous administration.

Dosage & Administration

• As directed by a physician. Dosage is dependent upon the age, weight and clinical condition of the patient as well as laboratory determinations. The dosage and constant infusion rate of intravenous dextrose must be selected with caution in pediatric patients, particularly neonates and low weight infants, because of the increased risk of hyperglycemia/ hypoglycemia. Additives may be incompatible. Administration Procedure:
• Check infusion set and infusion solution prior to use
• Pull moderately to tear off the protective cover of the Eurohead
• Hold lightly the Eurohead but not the bag
• Open the flow regulator fully and hold the giving set on the top white area, but not the membrane venting region
• Insert the spike of the administration set to the Eurohead and fit the connector of the administration set firmly to the needle
• Gradually allow the fluid to flow down to the needle tip and close
• Remove the protective cover of the needle
• Locate the veinpuncture site and clean the site with an antiseptic solution, and then insert the needle
• Securely tape the puncture site
• Securely tape the wings and tubing
• Start infusion while adjusting drip speed.

Interaction

There are no known drug interactions and none well documented.

Side Effects

Allergic reactions or anaphylactoid symptoms such as localized or generalized urticaria and pruritus; periorbital, facial, and/or laryngeal edema, coughing, sneezing, and/or difficulty with breathing have been reported during administration. The reporting frequency of these signs and symptoms is higher in women during pregnancy.

Pregnancy & Lactation

Teratogenic effect and pregnancy category C. This solution should be given to a pregnant woman only if clearly needed. It is not known whether this drug is excreted in human milk.

Precautions & Warnings

Do not uses if the solution is cloudy contain particles or date expired. Infusion of fluid should be immediately discontinued if rigor arises for any reason during the process.

Use in Special Populations

Pediatric Use: Safety and effectiveness of this solution in pediatric patients have not been established by adequate and well controlled trials.

Geriatric Use: Clinical studies of this solution did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

Therapeutic Class

Intravenous fluid preparations

Storage Conditions

Should be stored at controlled room temperature.

Disclaimer: This information is for reference only. Always consult a registered physician before taking any medicine.